ZA988461B - Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis - Google Patents

Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis

Info

Publication number
ZA988461B
ZA988461B ZA988461A ZA988461A ZA988461B ZA 988461 B ZA988461 B ZA 988461B ZA 988461 A ZA988461 A ZA 988461A ZA 988461 A ZA988461 A ZA 988461A ZA 988461 B ZA988461 B ZA 988461B
Authority
ZA
South Africa
Prior art keywords
restoring
methods
synergistic composition
cancerous growths
treating neoplastic
Prior art date
Application number
ZA988461A
Other languages
English (en)
Inventor
Nabil Hanna
Gary R Braslawsky
Kandasamy Harihara
Original Assignee
Idec Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idec Pharma Corp filed Critical Idec Pharma Corp
Publication of ZA988461B publication Critical patent/ZA988461B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ZA988461A 1997-09-18 1998-09-16 Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis ZA988461B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US93335997A 1997-09-18 1997-09-18

Publications (1)

Publication Number Publication Date
ZA988461B true ZA988461B (en) 1999-03-30

Family

ID=25463798

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA988461A ZA988461B (en) 1997-09-18 1998-09-16 Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis

Country Status (18)

Country Link
US (4) US20010018054A1 (forum.php)
EP (1) EP1015031A4 (forum.php)
JP (1) JP2001516727A (forum.php)
KR (1) KR100540267B1 (forum.php)
CN (1) CN1234413C (forum.php)
AR (1) AR013012A1 (forum.php)
AU (1) AU742216B2 (forum.php)
CA (1) CA2303178A1 (forum.php)
CO (1) CO4790100A1 (forum.php)
IL (2) IL134937A0 (forum.php)
IN (1) IN190792B (forum.php)
MY (1) MY131805A (forum.php)
NO (1) NO20001413L (forum.php)
RU (1) RU2219947C2 (forum.php)
SA (1) SA98190719B1 (forum.php)
TW (1) TWI252108B (forum.php)
WO (1) WO1999013912A1 (forum.php)
ZA (1) ZA988461B (forum.php)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197311B1 (en) 1991-07-25 2001-03-06 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
CN1406140A (zh) * 2000-02-28 2003-03-26 吉倪塞思公司 纳米胶囊包封系统与方法
US7244232B2 (en) * 2001-03-07 2007-07-17 Biomed Solutions, Llc Process for identifying cancerous and/or metastatic cells of a living organism
US20040038303A1 (en) * 2002-04-08 2004-02-26 Unger Gretchen M. Biologic modulations with nanoparticles
ES2392525T3 (es) * 2002-07-15 2012-12-11 F. Hoffmann-La Roche Ag Tratamiento del cáncer con el anticuerpo dirigido contra ErbB2 rhuMAb 2C4
US7491395B2 (en) 2002-11-20 2009-02-17 Bestewil Holding B.V. Compositions comprising antigen-complexes, method of making same as well as methods of using the antigen-complexes for vaccination
EP2204190A1 (en) 2003-07-15 2010-07-07 Chugai Seiyaku Kabushiki Kaisha IgM production by transformed cells and methods for quantifying said IgM production
CN100558894C (zh) * 2003-07-21 2009-11-11 P.安杰莱蒂分子生物学研究所 编码人表皮生长因子2/neu抗原的合成基因及其用途
UA92154C2 (ru) * 2004-08-03 2010-10-11 Транстек Фарма, Инк. Rage-слитые белки и способы их применения
GEP20105110B (en) 2004-08-03 2010-11-10 Transtech Pharma Inc Rage fusion proteins and their use
CA2634908C (en) * 2005-12-23 2015-05-19 Gcoder Systems Ab Positioning pattern
CN101410411A (zh) * 2006-02-09 2009-04-15 转化技术制药公司 Rage融合蛋白及使用方法
KR20090008459A (ko) 2006-05-05 2009-01-21 트랜스테크 파르마, 인크. Ｒａｇｅ 융합 단백질, 제제 및 이의 사용 방법
US20080199467A1 (en) * 2007-02-15 2008-08-21 Mjalli Adnan M M Immunoglobulin fusion proteins and methods of making
JP2011502964A (ja) 2007-10-23 2011-01-27 ザ レジェンツ オブ ザ ユニバーシティ オブ コロラド インバリアント鎖発現および／または異所性ｃｌｉｐ結合の競合的阻害剤
BRPI1015019A2 (pt) 2009-04-20 2018-02-14 Pfizer controle de glicosilação de proteína e composições e métodos relacionada a ele.
WO2011042548A1 (en) * 2009-10-09 2011-04-14 Sanofi-Aventis Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same
CA2817250A1 (en) * 2010-11-18 2012-05-24 The General Hospital Corporation Novel compositions and uses of anti-hypertension agents for cancer therapy
US9782452B2 (en) * 2011-11-22 2017-10-10 Cornell University Methods for stimulating hematopoietic recovery by inhibiting TGFβ signaling
WO2015027082A1 (en) 2013-08-22 2015-02-26 Acceleron Pharma, Inc. Tgf-beta receptor type ii variants and uses thereof
CN111700877A (zh) 2014-09-03 2020-09-25 吉倪塞思公司 治疗性纳米粒子和相关的组合物、方法和系统
EP4218792A1 (en) 2015-08-04 2023-08-02 Acceleron Pharma Inc. Composition for treating myeloproliferative disorders
TW202506185A (zh) 2017-01-20 2025-02-16 法商賽諾菲公司 抗TGF-β抗體及其用途
AU2018261131A1 (en) 2017-05-04 2019-11-07 Acceleron Pharma Inc. TGF-beta receptor type II fusion proteins and uses thereof
AU2019231205A1 (en) 2018-03-06 2020-09-24 The Trustees Of The University Of Pennsylvania Prostate-specific membrane antigen cars and methods of use thereof
CN114814223A (zh) * 2022-04-20 2022-07-29 昆明市妇幼保健院 一种用于监测及控制疟原虫治疗的系统及设备

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4052A (en) * 1845-05-13 Tktjss
US20020004052A1 (en) * 1990-05-08 2002-01-10 David Berd Composition comprising a tumor cell extract and method of using the composition
US5709860A (en) * 1991-07-25 1998-01-20 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
ES2117052T5 (es) * 1991-07-25 2004-12-01 Idec Pharmaceuticals Corporation Induccion de respuestas de linfocitos t citotoxicos.
US6197311B1 (en) 1991-07-25 2001-03-06 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
ES2174868T3 (es) 1992-10-29 2002-11-16 Celtrix Pharma Fragmento del receptor de fijacion a tgf-beta tipoii como agente terapeutico.
US5514670A (en) * 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
US5932212A (en) 1996-05-24 1999-08-03 Altus Biologics, Inc. Crosslinked protein crystal formulations and their use as catalysts in organic solvents

Also Published As

Publication number Publication date
TWI252108B (en) 2006-04-01
CN1234413C (zh) 2006-01-04
US20060153848A1 (en) 2006-07-13
KR100540267B1 (ko) 2006-01-10
CA2303178A1 (en) 1999-03-25
EP1015031A1 (en) 2000-07-05
IL134937A0 (en) 2001-05-20
IN190792B (forum.php) 2003-08-23
AU9565898A (en) 1999-04-05
US20010018054A1 (en) 2001-08-30
MY131805A (en) 2007-09-28
IL134937A (en) 2008-04-13
SA98190719B1 (ar) 2006-08-06
US6998125B2 (en) 2006-02-14
AU742216B2 (en) 2001-12-20
EP1015031A4 (en) 2004-03-17
HK1033653A1 (en) 2001-09-14
WO1999013912A1 (en) 1999-03-25
KR20010024109A (ko) 2001-03-26
US20040137014A1 (en) 2004-07-15
CN1279616A (zh) 2001-01-10
RU2219947C2 (ru) 2003-12-27
NO20001413D0 (no) 2000-03-17
US20010019715A1 (en) 2001-09-06
AR013012A1 (es) 2000-11-22
NO20001413L (no) 2000-05-18
JP2001516727A (ja) 2001-10-02
CO4790100A1 (es) 1999-05-31

Similar Documents

Publication Publication Date Title
IL134937A0 (en) Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis
EP0871494A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF TUMOR CELLS
SG99279A1 (en) Myoblast therapy for cosmetic treatment
EP0611302A4 (en) METHODS AND COMPOSITIONS FOR TREATING ALLERGIC REACTIONS.
ZA952356B (en) Skin treatment composition
EP0758196A4 (en) COMPOSITIONS AND METHODS FOR TREATING TUMORS
IL115766A0 (en) Composition and treatment for multiple sclerosis
IL114119A0 (en) Compositions and methods for the treatment of tumors
IL124650A0 (en) Methods and therapeutic compositions for treating cancer
IL113661A0 (en) Compositions and treatment for multiple sclerosis
IL111554A (en) Methods and compositions for hair treatment
HU9502722D0 (en) Amino-methyl-phosphonic- and amino-methyl-phosphinic-acid derivatives and their use for treating degenerative membrum diseases
EP0835092A4 (en) COMPOSITION AND TREATMENT FOR THE CONTROL OF Baldness
GB9405021D0 (en) Skin treatment composition
IL115224A0 (en) Preparations for use in the treatment of osteoporosis
SG65766A1 (en) Composition for preventing and treating gingival diseases
GB9217547D0 (en) Leather treatment compositions
GB9415901D0 (en) Novel compounds and treatment
ZA952120B (en) Skin treatment composition
PL331283A1 (en) Preparation for treating and/or preventing stupefaction
GB9415900D0 (en) Novel compounds and treatment
IL113444A0 (en) Compositions and methods for treating leukemia
ZA947964B (en) Compositions and methods for treating pathologies including cancer
GB9218774D0 (en) Synergistic composition for treating the skin
AU2197992A (en) Dihydropyrimido-quinoxalines and dihydropyrimido-pyridopyrazines useful for treating tumours